This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Real Estate Names: Simon Property (SPG) and National Health Investors (NHI)

Tipranks - Wed Aug 12, 6:16AM CDT

Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on Simon Property (SPG) and National Health Investors (NHI).

Claim 55% Off TipRanks

Simon Property (SPG)

Piper Sandler analyst Alexander Goldfarb maintained a Buy rating on Simon Property today and set a price target of $285.00. The company’s shares closed last Monday at $220.55.

According to TipRanks.com, Goldfarb is a 3-star analyst with an average return of 2.3% and a 49.4% success rate. Goldfarb covers the NA sector, focusing on stocks such as Innovative Industrial Properties, Hudson Pacific Properties, and Howard Hughes Holdings. ;'>

Currently, the analyst consensus on Simon Property is a Hold with an average price target of $223.53, a 1.1% upside from current levels. In a report issued on August 3, Bank of America Securities also maintained a Buy rating on the stock with a $264.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

National Health Investors (NHI)

Wells Fargo analyst John Kilichowski reiterated a Hold rating on National Health Investors today and set a price target of $79.00. The company’s shares closed last Monday at $74.15.

According to TipRanks.com, Kilichowski is a 4-star analyst with an average return of 7.5% and a 56.4% success rate. Kilichowski covers the NA sector, focusing on stocks such as National Healthcare Properties, Medical Properties Trust, and Healthpeak Properties. ;'>

National Health Investors has an analyst consensus of Moderate Buy, with a price target consensus of $82.20, implying a 9.3% upside from current levels. In a report issued on July 28, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $87.00 price target.

Read More on SPG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.